ArticleDiscover oncology2026
Computational multi-omics integration suggests an association between LAMA3 expression, immune suppression, and metabolic programs in pancreatic ductal adenocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spatiotemporal immune heterogeneity and precision immunotherapy for ovarian cancer.Clinical and translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in which immune dysregulation and metabolic remodeling are common features. Laminin subunit alpha 3 (LAMA3), a component of laminin-332 involved in cell–ECM adhesion and integrin-linked signaling, has not been systematically characterized in PDAC in a multi-omics context.
methodsWe conducted an in silico integrative multi-omics analysis using bulk and single-cell transcriptomic datasets, together with WGCNA, functional enrichment, immune deconvolution, CNV inference, pseudotime trajectory analysis, and regulatory network modeling. Candidate upstream regulators were explored computationally, and molecular docking was performed for hypothesis generation.
resultsLAMA3 showed higher expression in PDAC compared with non-tumor controls and was associated with pathways related to cell adhesion, extracellular matrix organization/remodeling, and immune-related programs. In bulk deconvolution analyses, higher LAMA3 expression was associated with increased macrophage-related signatures and lower estimated CD8⁺T-cell infiltration. Single-cell analyses indicated predominant expression in epithelial populations and higher CNV activity in LAMA3-high states; LAMA3 expression also tended to increase along inferred pseudotime trajectories, consistent with more advanced malignant epithelial programs. Enrichment analyses further linked LAMA3-high tumors to cell-cycle-, p53-related, and metabolic gene sets. Regulatory modeling prioritized EP300 as a putative upstream transcriptional regulator, and docking analyses suggested a potential interaction between Prostaglandin J2 and EP300, supporting an indirect, hypothesis-generating therapeutic avenue.
conclusionThis computational multi-omics study implicates LAMA3 as a candidate biomarker and a potential contributor to adhesion-associated tumor programs and an immunologically constrained microenvironment in PDAC. These findings are association-based and require experimental validation (e.g., functional perturbation and orthogonal immune profiling) before causal or therapeutic claims can be made.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.